Kristof Cuppens

MD MSc - Thoracic Oncology, master in hospital and health care management Hasselt - Belgium 🇧🇪 - PhD candidate Amsterdam/Leiden - he/him 🌈

[Kristof Cuppens @k_cupp_]

Extremely proud to announce that our NEOPREDICT-Lung study on neoadjuvant PD-1 and LAG-3 inhibition in resectable NSCLC is now online in @NatureMedicine . Without any doubt one the highlights of my career so far.
https://t.co/DHuktFCTtQ

[ESMO Open @ESMO_Open]

Global advances and future directions in lung cancer care: expert consensus and strategic priorities in @ESMO_Open. Important advances but global disparities, limited trial access, & implementation challenges still hinder progress. https://t.co/P3XbXn6e80

[Stephen V Liu, MD @StephenVLiu]

Update on CheckMate 77T (addition of perioperative nivolumab to neoadjuvant chemo in resectable NSCLC) @NatureCancer. In stage III N2+ NSCLC: EFS HR 0.46, 1y EFS 70% vs 45%, pCR 22% vs 5.6% - in multistation N2, EFS 0.43! Profound benefit here.

https://t.co/2JxQUQLyDK

[Kristof Cuppens @k_cupp_]

@DrJNaidoo @NatureComms @gecp_org @MARIANOPROVENCI Besides the very promising outcome of APOLO , this imo also provides more confidence for chemo-IO upfrontMDT-Bridge strategy in “borderline resectable” stage III NSCLC

[Kristof Cuppens @k_cupp_]

Our manuscript on Long-term outcomes of preoperative Nivolumab with or without Relatlimab in patients with resectable NSCLC (NEOpredict-Lung) is now online @JessaZiekenhuis @JessaWetenschap @GLW_UHasselt @hetAVL @LUMC_Leiden @UniklinikEssen https://t.co/UUTq2QTgJc

[Kristof Cuppens @k_cupp_]

@Alfdoc2 @charlesrudin Great potential, but toxicity - in particular ILD/pneumonitis - is concerning

[Kristof Cuppens @k_cupp_]

results of the phase I/II study of therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1 in NSCLC is now published in ESMO open @myESMO @JessaZiekenhuis @GLW_UHasselt @JessaWetenschap https://t.co/8uFPyTobNd

[Kristof Cuppens @k_cupp_]

Today at #WCLC2025 , our results of exhaled breath analysis of neoadjuvant ICI in resectable NSCLC. A new non-invasive biomarker of path response? @IASLC @JessaZiekenhuis @JessaWetenschap @LUMC_Leiden @hetAVL @GLW_UHasselt @breathomix

[Hidehito HORINOUCHI @HHorinouchi]

☑️#WCLC25 #LCSM Presidential🆙
🔥FLAURA2 Final Overall Survival
🔥First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC
🎙️ @dplanchard
@OncoAlert @Larvol @IASLC
https://t.co/YJWxTOHS12

[Kristof Cuppens @k_cupp_]

Phase III SAFFRON in EGFR+ NSCLC WITH MET-alteration post osi is still recruiting @JessaZiekenhuis @JessaWetenschap @GLW_UHasselt @Oncology_at_AZ

[MediMix @Medi_Mix]

🫁 #ASCO2025 In-Depth! Dr @k_cupp_ on SACHI :
✔️ Oral savolitinib + osi
✔️ PFS: 7–8 vs 4 mo vs chemo
✔️ Good tolerability
👀  Watch now https://t.co/v4Gf0RbGFN #MediMix #NSCLC #EGFR #MET

[MediMix @Medi_Mix]

🫁 #ASCO2025 In-Depth! Dr @k_cupp_ on SACHI :
✔️ Oral savolitinib + osi
✔️ PFS: 7–8 vs 4 mo vs chemo
✔️ Good tolerability
👀  Watch now https://t.co/v4Gf0RbGFN #MediMix #NSCLC #EGFR #MET

[Kristof Cuppens @k_cupp_]

And let’s not forget the proportion of patients that don’t even get to therapy due to inadequate testing for AGAs or have no access to appropriate treatments

[EGFR Resisters @EGFRResisters]

Real-world data on 1323 EGFR+ NSCLC pts on 1L osimertinib:

• Median OS: 28.6 mo
• High-risk pts:
 - TP53: 25.7
 - Brain mets: 24.3
 - Liver mets: 19.3
 - ECOG ≥2: 18.1

This isn’t good enough. Patients & families deserve more.
https://t.co/JpYjRhKkn8

[Giannis Mountzios @g_mountzios]

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :

✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001
✅ improved QoL (dyspnea and cough)
✅ 27% vs 62% G3 TRAEs

Grateful to all collaborators, @Amgen science team and above all our pts

[Stephen V Liu, MD @StephenVLiu]

#ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.

[Kristof Cuppens @k_cupp_]

Another breakthrough for our SCLC patients! Based on personal experience, this regimen is well tolerated when properly managed. Proud that our site @JessaZiekenhuis has yet again significantly contributed to a practice changing study.
@JessaWetenschap @GLW_UHasselt

[Sanjay Popat @DrSanjayPopat]

IMforte: RP3 maintenance lurbi+atezo ES-SCLC
CNS+ excluded. Enrolled post #4 chemo-atezo if non-PD. GCSF supported.
PFS HR=0.5: 2.1 to 5.5mo
OS HR=0.73: 10.6 to 13.2mo (from randomztn)
ORR 19.4 vs 10.4mo
AEs as expected

Bravo: a new standard of care #ASCO25

[Sanjay Popat @DrSanjayPopat]

IMforte: RP3 maintenance lurbi+atezo ES-SCLC
CNS+ excluded. Enrolled post #4 chemo-atezo if non-PD. GCSF supported.
PFS HR=0.5: 2.1 to 5.5mo
OS HR=0.73: 10.6 to 13.2mo (from randomztn)
ORR 19.4 vs 10.4mo
AEs as expected

Bravo: a new standard of care #ASCO25

[Noemi Reguart @NReguart]

🔂The earlier the better?
🧪 Who needs more treatment?
🎯 How to improve cure? 👏👏👏👏 @HendriksLizza #ASCO25

[Nicolas Girard @nicogirardcurie]

More patients cured with neoadjuvant immunotherapy: CheckMate-816 OS now in #NEJM #ASCO2025

[Kristof Cuppens @k_cupp_]

Results of Delphi-304 usher a new era for SCLC patients. Finally a truly game changer in the fight against this frightening disease. Immensely proud to have been part of this study. @ASCO @JessaZiekenhuis @JessaWetenschap @GLW_UHasselt @g_mountzios

https://t.co/nrFIN1XeNt

[Giannis Mountzios @g_mountzios]

Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for.
Grateful being involved and to our pts
Just out in @NEJM
Presentation today by 1@only @charlesrudin
#ASCO25